Payment overview · 2025
General Payments
$522.78
26 reported records · 10 companies
Healthcare provider profile · identity verified
John Thomas Hess, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · ARCADIA, FL · NPI 1861846115
Verified facts
What the public records show
CMS Open Payments records show John Thomas Hess, APRN received $522.78 in general payments during 2025 across 26 reported records.
Lundbeck LLC accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $211.33 | 40.4% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.86 | 12.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.85 | 12.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.91 | 10.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.49 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.88 | 5.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.97 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.56 | 3.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.23 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.70 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $522.78 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $226.03 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.86 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.85 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sertraline Hcl | Sertraline Hcl | 142 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 17 |
| Divalproex Sodium | Divalproex Sodium | 108 | 11 |
| Mirtazapine | Mirtazapine | 101 | 24 |
| Alprazolam | Alprazolam | 97 | 18 |
| Lorazepam | Lorazepam | 94 | 20 |
| Gabapentin | Gabapentin | 91 | 20 |
| Levetiracetam | Levetiracetam | 88 | 21 |
| Memantine Hcl | Memantine Hcl | 83 | 17 |
| Clonazepam | Clonazepam | 80 | 11 |
| Trazodone Hcl | Trazodone Hcl | 80 | 15 |
| Lamotrigine | Lamotrigine | 78 | 19 |
| Propranolol Hcl | Propranolol Hcl | 71 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 18 |
| Aripiprazole | Aripiprazole | 61 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 15 |
| Temazepam | Temazepam | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | suppressed |
| Topiramate | Topiramate | 45 | 13 |
| Olanzapine | Olanzapine | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 13 |
| Potassium Chloride | Potassium Chloride | 43 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 14 |
| Azithromycin | Azithromycin | 34 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 22 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Furosemide | Furosemide | 33 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Prednisone | Prednisone | 30 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 29 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 17 |
| Lisinopril | Lisinopril | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Perseris | Risperidone | 14 | suppressed |
| Tetrabenazine | Tetrabenazine | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $522.78 · 26 records | Lundbeck LLC | ABRYSVO, ACCRUFER, AIRSUPRA, COMIRNATY, FREESTYLE LIBRE 3, OTEZLA, PREVNAR 20, REPATHA, REXULTI, TRELEGY ELLIPTA, VRAYLAR, WATCHMAN FLX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error